141 related articles for article (PubMed ID: 18978733)
1. The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder.
Reid-Nicholson MD; Ramalingam P; Adeagbo B; Cheng N; Peiper SC; Terris MK
Mod Pathol; 2009 Jan; 22(1):119-27. PubMed ID: 18978733
[TBL] [Abstract][Full Text] [Related]
2. Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients.
Chuang KL; Chuang HC; Ng KF; Chang YH; Wu CT; Chuang CK; Liao SK; Pang ST
BJU Int; 2010 May; 105(10):1413-6. PubMed ID: 19818076
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Application of Fluorescence in Situ Hybridization in Diagnosing Urothelial Carcinoma.
Zhou H; Yan Y; Song L
Clin Lab; 2016 Oct; 62(10):2001-2009. PubMed ID: 28164542
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit).
Bravaccini S
Methods Mol Biol; 2021; 2292():35-48. PubMed ID: 33651350
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.
Bonberg N; Taeger D; Gawrych K; Johnen G; Banek S; Schwentner C; Sievert KD; Wellhäußer H; Kluckert M; Leng G; Nasterlack M; Stenzl A; Behrens T; Brüning T; Pesch B;
BJU Int; 2013 Aug; 112(4):E372-82. PubMed ID: 23350736
[TBL] [Abstract][Full Text] [Related]
6. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
7. Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients.
Nagai T; Okamura T; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Yasui T
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1271-1273. PubMed ID: 31030505
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer.
Kipp BR; Tyner HL; Campion MB; Voss JS; Karnes RJ; Sebo TJ; Halling KC; Zhang J
Am J Clin Pathol; 2008 Oct; 130(4):552-9. PubMed ID: 18794047
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer detection using FISH (UroVysion assay).
Halling KC; Kipp BR
Adv Anat Pathol; 2008 Sep; 15(5):279-86. PubMed ID: 18724101
[TBL] [Abstract][Full Text] [Related]
10. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
11. Vysis UroVysion for the detection of urothelial carcinoma.
Halling KC
Expert Rev Mol Diagn; 2003 Jul; 3(4):507-19. PubMed ID: 12877389
[TBL] [Abstract][Full Text] [Related]
12. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
[TBL] [Abstract][Full Text] [Related]
13. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
[TBL] [Abstract][Full Text] [Related]
14. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
[TBL] [Abstract][Full Text] [Related]
15. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
[TBL] [Abstract][Full Text] [Related]
16. UroVysion
Ke C; Liu X; Wan J; Hu Z; Yang C
Front Mol Biosci; 2023; 10():1250442. PubMed ID: 37867556
[No Abstract] [Full Text] [Related]
17. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Utility of UroVysion Combined With Conventional Urinary Cytology for Urothelial Carcinoma of the Upper Urinary Tract.
Sassa N; Iwata H; Kato M; Murase Y; Seko S; Nishikimi T; Hattori R; Gotoh M; Tsuzuki T
Am J Clin Pathol; 2019 Apr; 151(5):469-478. PubMed ID: 30668617
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue.
Reid-Nicholson MD; Motiwala N; Drury SC; Peiper SC; Terris MK; Waller JL; Ramalingam P
Ann Diagn Pathol; 2011 Feb; 15(1):37-45. PubMed ID: 21238914
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology.
Tapia C; Glatz K; Obermann EC; Grilli B; Barascud A; Herzog M; Schönegg R; Savic S; Bubendorf L
Cancer Cytopathol; 2011 Dec; 119(6):404-10. PubMed ID: 21732550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
